ストックスクリーナーアプリを入手
25.12
0.48%
-0.12
前日終値:
$25.24
開ける：
$25.1
24時間の取引高:
955.87K
Relative Volume:
0.37
時価総額：
$3.18B
収益：
$715.22M
当期純損益:
$-250.10M
株価収益率:
-12.37
EPS:
-2.03
ネットキャッシュフロー:
$-205.58M
1週間 パフォーマンス:
-0.16%
1か月 パフォーマンス:
+17.93%
6か月 パフォーマンス:
+45.12%
1年 パフォーマンス:
-21.28%
1日の値動き範囲:
$25.02
$25.33
1週間の範囲:
$24.56
$25.77
52週間の値動き範囲:
$16.10
$35.57
Apellis Pharmaceuticals Inc Stock (APLS) Company Profile
名前
Apellis Pharmaceuticals Inc
セクター
電話
617-977-5700
住所
100 FIFTH AVENUE, WALTHAM, KY
APLS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
APLS
Apellis Pharmaceuticals Inc
|
25.12 | 3.19B | 715.22M | -250.10M | -205.58M | -2.03 |
|
VRTX
Vertex Pharmaceuticals Inc
|
453.36 | 115.12B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
771.87 | 81.34B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.65 | 52.48B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
840.95 | 51.59B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
174.04 | 37.13B | 447.02M | -1.18B | -906.14M | -6.1812 |
Apellis Pharmaceuticals Inc Stock (APLS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-11-06 | 開始されました | Wolfe Research | Peer Perform |
| 2025-10-15 | 開始されました | Wells Fargo | Overweight |
| 2025-09-26 | ダウングレード | Goldman | Neutral → Sell |
| 2025-05-09 | ダウングレード | BofA Securities | Buy → Neutral |
| 2025-05-09 | ダウングレード | Raymond James | Strong Buy → Outperform |
| 2025-04-29 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-12-17 | ダウングレード | Goldman | Buy → Neutral |
| 2024-11-21 | 開始されました | Morgan Stanley | Equal-Weight |
| 2024-10-25 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2024-10-16 | 開始されました | Scotiabank | Sector Outperform |
| 2024-10-16 | 開始されました | William Blair | Outperform |
| 2024-05-31 | 開始されました | Piper Sandler | Neutral |
| 2024-02-05 | アップグレード | Jefferies | Hold → Buy |
| 2023-12-14 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2023-11-09 | 開始されました | Goldman | Buy |
| 2023-11-02 | 開始されました | Mizuho | Neutral |
| 2023-10-06 | アップグレード | JP Morgan | Neutral → Overweight |
| 2023-09-15 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2023-08-29 | 繰り返されました | Citigroup | Buy |
| 2023-08-03 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2023-08-01 | ダウングレード | BofA Securities | Buy → Neutral |
| 2023-01-03 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2022-11-10 | ダウングレード | Jefferies | Buy → Hold |
| 2022-07-19 | 開始されました | H.C. Wainwright | Buy |
| 2022-06-17 | 再開されました | Stifel | Buy |
| 2022-04-14 | ダウングレード | ROTH Capital | Neutral → Sell |
| 2021-12-08 | 開始されました | Wells Fargo | Overweight |
| 2021-11-29 | ダウングレード | ROTH Capital | Buy → Neutral |
| 2021-09-10 | 繰り返されました | BMO Capital Markets | Outperform |
| 2021-09-10 | 繰り返されました | Credit Suisse | Neutral |
| 2021-09-10 | 繰り返されました | Needham | Buy |
| 2021-09-10 | 繰り返されました | Oppenheimer | Outperform |
| 2021-09-10 | ダウングレード | Wedbush | Outperform → Neutral |
| 2021-08-19 | 開始されました | Jefferies | Buy |
| 2021-08-19 | アップグレード | Wedbush | Neutral → Outperform |
| 2021-05-21 | 開始されました | UBS | Buy |
| 2021-04-16 | 開始されました | Goldman | Buy |
| 2020-11-19 | 開始されました | Needham | Buy |
| 2020-09-01 | 開始されました | Stifel | Buy |
| 2020-07-20 | 開始されました | ROTH Capital | Buy |
| 2020-06-17 | 開始されました | BTIG Research | Neutral |
| 2020-04-01 | 開始されました | Raymond James | Strong Buy |
| 2020-03-31 | 開始されました | BMO Capital Markets | Outperform |
| 2020-03-11 | アップグレード | Wedbush | Underperform → Neutral |
| 2020-01-07 | 開始されました | SVB Leerink | Mkt Perform |
| 2019-12-19 | 開始されました | BofA/Merrill | Buy |
| 2019-11-22 | 開始されました | Wedbush | Underperform |
| 2019-11-05 | 開始されました | Credit Suisse | Neutral |
| 2019-08-01 | 繰り返されました | Cantor Fitzgerald | Overweight |
| 2019-07-12 | アップグレード | JP Morgan | Neutral → Overweight |
| 2019-03-29 | 開始されました | Robert W. Baird | Outperform |
| 2019-01-23 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2018-07-30 | アップグレード | B. Riley FBR | Neutral → Buy |
| 2018-05-24 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-04-12 | ダウングレード | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-02-08 | 開始されました | B. Riley FBR, Inc. | Buy |
すべてを表示
Apellis Pharmaceuticals Inc (APLS) 最新ニュース
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Receives Average Rating of "Hold" from Analysts - MarketBeat
Apellis Pharmaceuticals shows rising relative price performance; still shy of key benchmark - MSN
Simplify Asset Management Inc. Buys New Stake in Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Institution Moves: How buybacks impact Apellis Pharmaceuticals Inc stock valueJuly 2025 Opening Moves & Weekly Stock Breakout Alerts - moha.gov.vn
Apellis Pharmaceuticals' chief commercial officer sells shares worth $101,103 - MSN
Understanding Momentum Shifts in (APLS) - Stock Traders Daily
How risky is Apellis Pharmaceuticals Inc. (1JK) stock compared to peersMarket Timing Techniques & Free Get High Impact Recommendations - bollywoodhelpline.com
Highland Capital Management LLC Takes Position in Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Apellis Pharmaceuticals Earnings Notes - Trefis
How sustainable is Apellis Pharmaceuticals Inc. stock dividend payoutInstitutional Buying Trends & Affordable Investment Portfolio - bollywoodhelpline.com
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Apellis Pharmaceuticals (APLS) and Argenx Se (ARGX) - The Globe and Mail
Mizuho Securities Maintains Apellis Pharmaceuticals(APLS.US) With Hold Rating - 富途牛牛
Will Apellis Pharmaceuticals Inc. (1JK) stock outperform foreign stocksEarnings Risk Report & Reliable Volume Spike Trade Alerts - Улправда
Why Apellis Pharmaceuticals Inc. stock appeals to dividend seekersWeekly Trade Recap & High Conviction Buy Zone Picks - Улправда
Will Apellis Pharmaceuticals Inc. stock see PE expansion2025 Trading Recap & Reliable Price Breakout Signals - Улправда
Stifel maintains Apellis Pharmaceuticals (APLS) buy recommendation - MSN
APLS (Apellis Pharmaceuticals) EV-to-OCF : 39.23 (As of Dec. 19, 2025) - GuruFocus
Apellis Pharmaceuticals stock price target lowered to $48 at Stifel By Investing.com - Investing.com Canada
Stifel Lowers Price Target for Apellis Pharmaceuticals (APLS) to $48 | APLS Stock News - GuruFocus
Stifel Nicolaus Cuts Apellis Pharmaceuticals (NASDAQ:APLS) Price Target to $48.00 - MarketBeat
Is Apellis Pharmaceuticals Inc. stock near bottom after decline2025 Pullback Review & AI Forecasted Entry and Exit Points - DonanımHaber
What technical charts say about Apellis Pharmaceuticals Inc. stock2025 Technical Overview & Comprehensive Market Scan Insights - Улправда
Insider Selling: Apellis Pharmaceuticals (NASDAQ:APLS) General Counsel Sells 5,000 Shares of Stock - MarketBeat
Precision Trading with Apellis Pharmaceuticals Inc. (APLS) Risk Zones - Stock Traders Daily
Officer Watson Sells 5,000 ($122.5K) Of Apellis Pharmaceuticals Inc [APLS] - TradingView — Track All Markets
[Form 4] Apellis Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan
Investors in Apellis Pharmaceuticals (NASDAQ:APLS) From Five Years Ago Are Still Down 54%, Even After 3.2% Gain This Past Week - 富途牛牛
Officer Watson Files To Sell 5,000 Of Apellis Pharmaceuticals Inc [APLS] - TradingView — Track All Markets
Hudson Bay Capital Management LP Has $8.22 Million Stock Holdings in Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Apellis stock rating reiterated at Outperform by William Blair - Investing.com Canada
Squarepoint Ops LLC Cuts Stock Holdings in Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Braidwell LP Sells 531,300 Shares of Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
683 Capital Management LLC Buys 77,000 Shares of Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Apellis Pharmaceuticals: A Good Product That Just Misses The Mark (NASDAQ:APLS) - Seeking Alpha
Natixis Sells 564,361 Shares of Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Camber Capital Management LP Acquires New Holdings in Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Bank of Nova Scotia Makes New Investment in Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Apellis Pharmaceuticals Inc Stock Analysis and ForecastRetail Trading Trends & Low Cost Wealth Building - earlytimes.in
Mizuho Lowers Price Target on Apellis Pharmaceuticals (APLS) Amid Ongoing Eye Disease Therapy Challenges - MSN
Apellis Pharmaceuticals, Inc. $APLS Shares Purchased by Amundi - MarketBeat
Jump Financial LLC Buys 293,075 Shares of Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Ossiam Takes $9.62 Million Position in Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Would You Still Hold Apellis Pharmaceuticals Stock If It Fell 30%? - Trefis
Technical Reactions to APLS Trends in Macro Strategies - news.stocktradersdaily.com
Marshall Wace LLP Buys 2,681,263 Shares of Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Norges Bank Takes Position in Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Apellis Pharmaceuticals (APLS) Surges 17.6% on Higher Price Target - MSN
Apellis Post Hoc Analysis Confirms Long-Term Benefit of SYFOVRE for Geographic Atrophy - MSN
Apellis Pharmaceuticals (NASDAQ:APLS) Stock Price Up 6.2%Still a Buy? - MarketBeat
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Given Average Rating of "Hold" by Analysts - MarketBeat
Apellis shares jump 12% following FDA approval of first-ever C3G treatment - MSN
Apellis Pharmaceuticals Inc (APLS) 財務データ
収益
当期純利益
現金流量
EPS
0.90%
大文字化:
|
ボリューム (24 時間):